investment analyst coverage
Craig-Hallum Initiates Coverage of Guardant Health With Buy Rating
The investment bank focused mainly on its expectations for Guardant's colorectal cancer screening assay, but also argued its overall business is poised for significant growth.
Craig-Hallum Downgrades Exact Sciences to Hold, Lowers Price Target to $35
Analysts for the bank cited expected competition from Guardant Health's blood-based colorectal cancer test, as well as market challenges for Exact's Cologuard.
Canaccord Initiates Coverage of Guardant Health With Buy Rating
The investment bank gave the liquid biopsy company a price target of $90 and said that it views Guardant as the field leader.